Acquisition of lymphokine-producing phenotype by CD4+ T cells
- PMID: 7912089
- DOI: 10.1146/annurev.iy.12.040194.003223
Acquisition of lymphokine-producing phenotype by CD4+ T cells
Abstract
Naive CD4+ T cells when stimulated produce IL-2 as their major lymphokine. Upon priming, these cells develop into cells that produce either IFN gamma, TNF beta, and IL-2 or IL-4 and its congeners. The former cells are designated TH1-like, and the latter TH2-like. Here we review the regulation of the differentiation of naive CD4 cells into IFN gamma- or IL-4-producers. The dominant factors that determine such differentiation are lymphokines and other cytokines. IL-2 itself appears to be required for naive cells to develop into TH1- or TH2-like cells but is not deterministic of their differentiation fate. If IL-4 is also present during the priming period, the resultant CD4+ T cells produce IL-4 upon restimulation; the development of IFN gamma-producing cells is strikingly inhibited by IL-4. In the absence of IL-4, priming for IFN gamma-production occurs, but this is markedly enhanced by IL-12. The role of IFN gamma in enhancing priming for IFN gamma-production is not fully resolved. In some in vitro systems, it appears to act together with IL-12 to enhance such production. Anti-IFN gamma diminishes priming for IFN gamma production in vivo. Lymphokines also exert a "cross-regulatory" or inhibitory effect. As noted above, IL-4 strikingly diminishes priming for IFN gamma production, although this inhibitory effect is blunted in the presence of IL-12. IFN gamma similarly diminishes priming for IL-4 production; this effect is principally observed when low concentrations of IL-4 are used in the priming culture. Although other factors may play a role in the determination of lymphokine-producing phenotype, such as antigen dose, type of antigen-presenting cell, and expression of accessory molecules and hormones, these effects appear to be secondary to the dominant role of the lymphokines and cytokines.
Similar articles
-
Acute induction and priming for cytokine production in lymphocytes.Cytokine Growth Factor Rev. 1996 Aug;7(2):123-32. doi: 10.1016/1359-6101(96)00018-4. Cytokine Growth Factor Rev. 1996. PMID: 8899290 Review.
-
High-dose IL-2 and IL-15 enhance the in vitro priming of naive CD4+ T cells for IFN-gamma but have differential effects on priming for IL-4.J Immunol. 1996 Apr 1;156(7):2413-22. J Immunol. 1996. PMID: 8786299
-
IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells.J Immunol. 1993 Aug 15;151(4):1938-49. J Immunol. 1993. PMID: 8102154
-
Heterogeneity in lymphokine profiles of CD4+ and CD8+ T cells and clones activated in vivo and in vitro.Immunol Rev. 1991 Oct;123:85-114. doi: 10.1111/j.1600-065x.1991.tb00607.x. Immunol Rev. 1991. PMID: 1684785 Review.
-
Central role for TCR/CD3 ligation in the differentiation of CD4+ T cells toward A Th1 or Th2 functional phenotype.J Immunol. 1992 Jan 1;148(1):47-54. J Immunol. 1992. PMID: 1345789
Cited by
-
Rocaglamide promotes infiltration and differentiation of T cells and coordinates with PD-1 inhibitor to overcome checkpoint resistance in multiple tumor models.Cancer Immunol Immunother. 2024 Jun 4;73(8):137. doi: 10.1007/s00262-024-03706-5. Cancer Immunol Immunother. 2024. PMID: 38833034 Free PMC article.
-
A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis.Biomedicines. 2023 Dec 6;11(12):3229. doi: 10.3390/biomedicines11123229. Biomedicines. 2023. PMID: 38137450 Free PMC article. Review.
-
Effect of COVID-19 mRNA Vaccine on Human Lung Carcinoma Cells In Vitro by Means of Raman Spectroscopy and Imaging.ACS Omega. 2023 Oct 30;8(45):42555-42564. doi: 10.1021/acsomega.3c05287. eCollection 2023 Nov 14. ACS Omega. 2023. PMID: 38024689 Free PMC article.
-
Atherosclerosis: The Involvement of Immunity, Cytokines and Cells in Pathogenesis, and Potential Novel Therapeutics.Aging Dis. 2023 Aug 1;14(4):1214-1242. doi: 10.14336/AD.2022.1208. Aging Dis. 2023. PMID: 37163428 Free PMC article. Review.
-
Recombinant HBsAg of the Wild-Type and the G145R Escape Mutant, included in the New Multivalent Vaccine against Hepatitis B Virus, Dramatically Differ in their Effects on Leukocytes from Healthy Donors In Vitro.Vaccines (Basel). 2022 Feb 3;10(2):235. doi: 10.3390/vaccines10020235. Vaccines (Basel). 2022. PMID: 35214692 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials